Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

SB 2388Session 2025

What changed between versions

16 paragraphs changed+86 words added−213 removed

Highlighted text was added in the newer version. Struck-through text was removed.

MISSISSIPPI LEGISLATURE

2025 Regular Session

To: Medicaid; Insurance

Adopted

AMENDMENT NO 1 PROPOSED TO

Cmte Sub for Senate Bill No. 2388

ByBY: Senator(s) Blackwell

Senate Bill 2388

(COMMITTEE SUBSTITUTE)

AN ACT TO PROVIDE THAT THE DIVISION OF MEDICAID, IN ESTABLISHING AND MAINTAINING THE PREFERRED DRUG LIST, SHALL ENSURE THAT NO NONOPIOID DRUG APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OR MANAGEMENT OF PAIN SHALL BE DISADVANTAGED OR DISCOURAGED WITH RESPECT TO COVERAGE RELATIVE TO ANY OPIOID OR NARCOTIC DRUG FOR THE TREATMENT OR MANAGEMENT OF PAIN ON SUCH PREFERRED DRUG LIST; AND FOR RELATED PURPOSES.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

AMEND after line 31 by inserting the following language as a new section and renumbering the subsequent sections:

SECTION 1*. Pain relief parity in Medicaid. (1) In establishing and maintaining the preferred drug list, the division shall ensure that no nonopioidnonstatin drugmedication approvedthat byhas a unique indication to reduce the Unitedrisk Statesof Fooda major cardiovascular event in primary prevention and Drugsecondary Administrationprevention for the treatment or management of painpatients shall be disadvantaged or discouraged with respect to coverage relative to any opioid or narcotic drug for the treatment or management of paincardiovascular events on such preferred drug list, where impermissible disadvantaging or discouragement includes, without limitation: designating any such nonopioidcardiovascular drug as a nonpreferred drug if any opioid or narcoticcardiovascular drug is designated as a preferred drug; or establishing more restrictive or more extensive utilization controls, including, but not limited to, more restrictive or more extensive clinical review, prior authorization or step therapy requirements, for such nonopioid drug than the least restrictive or extensive utilization controls applicable to any such opioidother or narcoticcardiovascular drug. This section also applies to drugs being provided under a contract between the division and any managed care organization.

(2) This section shall apply to a nonopioid drug immediately upon its approval by the United States Food and Drug Administration for the treatment or management of pain, regardless of whether such drug has been reviewed by the division for inclusion on the preferred drug list. This section also applies to drugs being provided under a contract between the division and any managed care organization.

SECTION 2. This act shall take effect and be in force from and after July 1, 2025.

FURTHER, AMEND the title to conform.

Back to the full text